| Shangqin Liu,Chengsi Gui. Megakaryocyte aplastic thrombocytopenia after CAR T-cell therapy in a patient with multiple myeloma: A case report. Oncol Transl Med, 2021, 7: 45-47. |
| Megakaryocyte aplastic thrombocytopenia after CAR T-cell therapy in a patient with multiple myeloma: A case report |
| Received:August 09, 2020 Revised:February 22, 2021 |
| View Full Text View/Add Comment Download reader |
| KeyWord:megakaryocyte aplastic thrombocytopenia; chimeric antigen receptor (CAR) T cell therapy; multiple myeloma; case report |
| Author Name | Affiliation | E-mail | | Shangqin Liu | Department of Hematology, Zhongnan Hospital of Wuhan University | ubeliu@aliyun.com | | Chengsi Gui | Department of Hematology, Zhongnan Hospital of Wuhan University | |
|
| Hits: 7339 |
| Download times: 8895 |
| Abstract: |
| Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment strategy for hematologic
malignancies. The success of CAR T-cell therapy in treating leukemia and lymphoma has promoted
its development for multiple myeloma (MM), and the initial results of CAR T cell therapy have been
encouraging. CAR T-cell therapy target antigens that have been clinically evaluated in MM; these antigens
include CD19, B cell maturation antigen (BCMA), CD38, and CD138. A barrier to the widespread use of
CAR T-cell therapy is its toxicity, primarily cytokine release syndrome (CRS), and neurologic toxicity. This
study reports a patient with refractory MM who also developed megakaryocyte aplastic thrombocytopenia
after receiving CAR T-cell therapy; such a case or the unusual side effects involving medications are yet
unreported. There are risks in using cyclosporine and other immunosuppressants that may lead to MM
recurrence as the use of such substances is contradictory to previous treatments; therefore, we temporarily
administered platelet infusion as supportive care. Thus far, the condition of the patient has been steady and
the patient regularly takes blood test in the hospital. |
| Close |
|
|
|